AB Share Price

Open 10.13 Change Price %
High 10.43 1 Day 0.24 2.37
Low 10.07 1 Week 0.35 3.49
Close 10.37 1 Month 0.04 0.39
Volume 89563 1 Year -3.42 -24.80
52 Week High 18.07
52 Week Low 9.09
AB Important Levels
Resistance 2 10.70
Resistance 1 10.57
Pivot 10.29
Support 1 10.17
Support 2 10.04
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
APAM 33.78 15.72%
APAM 33.78 15.72%
OXI 0.08 14.29%
OXI 0.08 14.29%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
GDMS 692.00 -10.00%
CIB 0.10 -9.09%
CIB 0.10 -9.09%
CIB 0.10 -9.09%
CIB 0.10 -9.09%
MLZAM 1.65 -8.33%
MLOLM 10.50 -7.98%
HBW 0.15 -6.25%
ALPHY 13.00 -4.90%
JXR 0.62 -4.62%
More..

AB Science (EPA: AB)

AB Technical Analysis 2
As on 16th Aug 2017 AB Share Price closed @ 10.37 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 12.43 & Buy for SHORT-TERM with Stoploss of 10.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
AB Target for August
1st Target up-side 10.31
2nd Target up-side 10.65
3rd Target up-side 11
1st Target down-side 9.31
2nd Target down-side 8.97
3rd Target down-side 8.62
AB Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.ab-science.com
AB Address
AB
3, Avenue George V
Paris, 75008
France
Phone: 33 1 47 20 00 14
Fax: 33 1 47 20 24 11
AB Latest News
Interactive Technical Analysis Chart AB Science ( AB EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AB Science
AB Business Profile
AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.